Roche scores a suc­cess for Ale­cen­sa PhI­II; FDA sched­ules Ad­Comm for Hep­lisav-B; New CMO at Sarep­ta

→ Roche re­port­ed this morn­ing that its lat­est Phase III study for Ale­cen­sa (alec­tinib) came through, hit­ting the end­point on pro­gres­sion-free sur­vival for non-small cell lung can­cer pa­tients who had failed chemo com­bined with crizo­tinib. “We are pleased to an­nounce that the re­sults of the phase III ALUR tri­al fur­ther sup­port the use of Ale­cen­sa as a treat­ment for peo­ple with ALK-pos­i­tive lung can­cer who, af­ter hav­ing pro­gressed on both chemother­a­py and crizo­tinib, are in need of new treat­ment op­tions,” said San­dra Horn­ing, Chief Med­ical Of­fi­cer and Head of Glob­al Prod­uct De­vel­op­ment. “The re­sults of this tri­al will sup­port our ac­cess dis­cus­sions with glob­al health au­thor­i­ties as we seek to bring Ale­cen­sa to pa­tients faster.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER